These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 28675187

  • 21. Molecular targets and therapeutic interventions for iron induced neurodegeneration.
    Bagwe-Parab S, Kaur G.
    Brain Res Bull; 2020 Mar; 156():1-9. PubMed ID: 31866454
    [Abstract] [Full Text] [Related]

  • 22. Coexistence of Copper in the Iron-Rich Particles of Aceruloplasminemia Brain.
    Yoshida K, Hayashi H, Wakusawa S, Shigemasa R, Koide R, Ishikawa T, Tatsumi Y, Kato K, Ohara S, Ikeda SI.
    Biol Trace Elem Res; 2017 Jan; 175(1):79-86. PubMed ID: 27272717
    [Abstract] [Full Text] [Related]

  • 23. Iron: effect of overload and deficiency.
    Hider RC, Kong X.
    Met Ions Life Sci; 2013 Jan; 13():229-94. PubMed ID: 24470094
    [Abstract] [Full Text] [Related]

  • 24. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F, Phatak P.
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [Abstract] [Full Text] [Related]

  • 25. Optimizing the diagnosis and the treatment of iron overload diseases.
    Brissot P.
    Expert Rev Gastroenterol Hepatol; 2016 Jan; 10(3):359-70. PubMed ID: 26561304
    [Abstract] [Full Text] [Related]

  • 26. Iron mobilization using chelation and phlebotomy.
    Flaten TP, Aaseth J, Andersen O, Kontoghiorghes GJ.
    J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
    [Abstract] [Full Text] [Related]

  • 27. The role of iron in patients after bone marrow transplantation.
    de Witte T.
    Blood Rev; 2008 Dec; 22 Suppl 2():S22-8. PubMed ID: 19059053
    [Abstract] [Full Text] [Related]

  • 28. The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
    Kontoghiorghes GJ, Kolnagou A, Skiada A, Petrikkos G.
    Hemoglobin; 2010 Jun; 34(3):227-39. PubMed ID: 20524813
    [Abstract] [Full Text] [Related]

  • 29. Chemical features of in use and in progress chelators for iron overload.
    Nurchi VM, Crisponi G, Lachowicz JI, Medici S, Peana M, Zoroddu MA.
    J Trace Elem Med Biol; 2016 Dec; 38():10-18. PubMed ID: 27365273
    [Abstract] [Full Text] [Related]

  • 30. Iron overload and chelation.
    Hershko C, Link G, Konijn AM, Ioav Cabantchik Z.
    Hematology; 2005 Dec; 10 Suppl 1():171-3. PubMed ID: 16188664
    [Abstract] [Full Text] [Related]

  • 31. Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability.
    Fasano A, Colosimo C, Miyajima H, Tonali PA, Re TJ, Bentivoglio AR.
    Mov Disord; 2008 Apr 15; 23(5):751-5. PubMed ID: 18200628
    [Abstract] [Full Text] [Related]

  • 32. Ferritin and iron studies in anaemia and chronic disease.
    Peng YY, Uprichard J.
    Ann Clin Biochem; 2017 Jan 15; 54(1):43-48. PubMed ID: 27701066
    [Abstract] [Full Text] [Related]

  • 33. Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation.
    Meo A, Ruggeri A, La Rosa MA, Zanghì L, Morabito N, Duca L.
    Hemoglobin; 2006 Jan 15; 30(1):131-7. PubMed ID: 16540426
    [Abstract] [Full Text] [Related]

  • 34. Iron chelation therapy to prevent the manifestations of aceruloplasminemia.
    Bove F, Fasano A.
    Neurology; 2015 Sep 22; 85(12):1085-6. PubMed ID: 26311749
    [No Abstract] [Full Text] [Related]

  • 35. Current and future treatment strategies for iron overload cardiomyopathy.
    Wongjaikam S, Kumfu S, Chattipakorn SC, Fucharoen S, Chattipakorn N.
    Eur J Pharmacol; 2015 Oct 15; 765():86-93. PubMed ID: 26291660
    [Abstract] [Full Text] [Related]

  • 36. Identification and in silico characterization of a novel compound heterozygosity associated with hereditary aceruloplasminemia.
    Hofmann WP, Welsch C, Takahashi Y, Miyajima H, Mihm U, Krick C, Zeuzem S, Sarrazin C.
    Scand J Gastroenterol; 2007 Sep 15; 42(9):1088-94. PubMed ID: 17710675
    [Abstract] [Full Text] [Related]

  • 37. Iron overload and chelation therapy in myelodysplastic syndromes.
    Temraz S, Santini V, Musallam K, Taher A.
    Crit Rev Oncol Hematol; 2014 Jul 15; 91(1):64-73. PubMed ID: 24529413
    [Abstract] [Full Text] [Related]

  • 38. Role of Iron in the Molecular Pathogenesis of Diseases and Therapeutic Opportunities.
    Abbasi U, Abbina S, Gill A, Takuechi LE, Kizhakkedathu JN.
    ACS Chem Biol; 2021 Jun 18; 16(6):945-972. PubMed ID: 34102834
    [Abstract] [Full Text] [Related]

  • 39. Hepatic iron overload or cirrhosis may occur in acquired copper deficiency and is likely mediated by hypoceruloplasminemia.
    Thackeray EW, Sanderson SO, Fox JC, Kumar N.
    J Clin Gastroenterol; 2011 Feb 18; 45(2):153-8. PubMed ID: 20502350
    [Abstract] [Full Text] [Related]

  • 40. Design of iron chelators with therapeutic application.
    Zhou T, Ma Y, Kong X, Hider RC.
    Dalton Trans; 2012 Jun 07; 41(21):6371-89. PubMed ID: 22391807
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.